


## PHARMACEUTICAL 2022

## Viking Therapeutics Inc. Rank 52 of 466





## PHARMACEUTICAL 2022



## Viking Therapeutics Inc. Rank 52 of 466

The relative strengths and weaknesses of Viking Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Viking Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 70% points. The greatest weakness of Viking Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 266%, being 188% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	210,528
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,778
Liabilities, Non-Current	0
Other Assets	134
Other Compr. Net Income	-495
Other Expenses	0
Other Liabilities	0
Other Net Income	692
Other Revenues	0
Property and Equipment	0
Research and Development	44,981
Selling, General and Administrative Expense	10,701

Output Variable	Value in 1000 USD
Assets	210,662
Liabilities	8,778
Expenses	55,682
Revenues	0
Stockholders Equity	201,884
Net Income	-54,990
Comprehensive Net Income	-55,238
Economic Capital Ratio	266%

